Abstract
Treatments for multiple myeloma (MM) have been rapidly evolving. Newly developed treatment regimens are likely to be more effective but also cost more than conventional therapies. We conducted a systematic review to compare the cost effectiveness of different classes of MM treatment. We searched the PubMed, MEDLINE, Web of Science, and EMBASE databases for studies published during 1990-2018 comparing the cost effectiveness of transplant, chemotherapeutic and novel MM treatments. Titles and abstracts were independently reviewed for eligibility by two investigators. The quality of the included studies was evaluated using the 16-item, validated Quality of Health Economics Studies instrument. Twenty-four publications were included in the systematic review and summarized according to treatment regimen and line. For first-line treatment, transplant was the most cost-effective option for transplant-eligible MM patients [the incremental cost-effectiveness ratio (ICER) was $4053-€45,460 per quality-adjusted life-year (QALY) gained, and $3848-$72,852 per life-year gained (LYG)], and the ICER for novel agents compared with conventional chemotherapy was $59,076 per QALY and $220,681 per LYG. For second-line treatment, in comparisons of nov...Continue Reading
References
Jul 10, 2001·British Journal of Haematology·F C SampsonE Vandenberghe
Jan 25, 2003·Medical Care·Chiun-Fang ChiouJoshua J Ofman
Apr 15, 2003·Leukemia & Lymphoma·C Tom KouroukisRalph Meyer
May 7, 2003·The Lancet Oncology·Ambuj KumarBenjamin Djulbegovic
Sep 18, 2010·European Journal of Haematology·John HornbergerMikael Löthgren
May 13, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jennifer G GaultneyCarin A Uyl-de Groot
Sep 7, 2011·Journal of Medical Economics·Jörgen MöllerAnanthram Murthy
May 11, 2012·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Ruth E BrownSteve Schey
Jan 10, 2013·The Oncologist·Louis P GarrisonMei Sheng Duh
Apr 19, 2013·Cancer Management and Research·V FragoulakisN Maniadakis
Oct 8, 2013·PloS One·Alessandro CorsoLorenzo G Mantovani
Jul 22, 2014·Clinical Transplantation·Chintan PandyaShaji K Kumar
Jul 26, 2014·Oncology·Miriam Y KimSikander Ailawadhi
Dec 6, 2014·PharmacoEconomics·Wei ZhangAslam H Anis
Apr 22, 2015·European Journal of Haematology·Hedwig M BlommesteinCarin A Uyl-de Groot
Jun 3, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Gunjan L ShahSusan K Parsons
Oct 31, 2015·Journal of Medical Economics·S Z UsmaniT Facon
Mar 25, 2016·Journal of Clinical Pharmacy and Therapeutics·P M AguiarS Storpirtis
Apr 29, 2016·Acta Oncologica·Sixten BorgUlf Persson
May 25, 2016·ClinicoEconomics and Outcomes Research : CEOR·Wendong ChenHuan Zhan
Oct 18, 2016·Journal of Medical Economics·Andrzej J JakubowiakSumeet Panjabi
Jul 2, 2016·Journal of Hematology & Oncology·Leonard Naymagon, Maher Abdul-Hay
Feb 12, 2017·Journal of the National Comprehensive Cancer Network : JNCCN·Shaji K KumarRashmi Kumar
Feb 15, 2017·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Shankar PrinjaSubhash Varma
Apr 5, 2017·Journal of the National Cancer Institute·Ahmedin JemalHannah K Weir
Jul 25, 2017·Journal of Managed Care & Specialty Pharmacy·Ying ChenXianglin L Du
Oct 3, 2017·Clinical Therapeutics·Christopher G PelligraSikander Ailawadhi
Oct 14, 2017·Expert Review of Hematology·Andrzej J JakubowiakSikander Ailawadhi
Jan 2, 2018·Journal of Managed Care & Specialty Pharmacy·Josh J CarlsonDaniel A Ollendorf
Feb 3, 2018·European Journal of Haematology·Pauline GueneauMathieu Boulin
Mar 27, 2018·Clinical Lymphoma, Myeloma & Leukemia·Evangelos Terpos, UNKNOWN International Myeloma Society
May 21, 2019·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Joel W Hay